1. Home
  2. CHRD vs GKOS Comparison

CHRD vs GKOS Comparison

Compare CHRD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chord Energy Corporation

CHRD

Chord Energy Corporation

HOLD

Current Price

$92.00

Market Cap

5.3B

Sector

Energy

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$113.29

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRD
GKOS
Founded
2007
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
6.4B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
CHRD
GKOS
Price
$92.00
$113.29
Analyst Decision
Buy
Strong Buy
Analyst Count
11
14
Target Price
$131.20
$127.71
AVG Volume (30 Days)
659.3K
641.9K
Earning Date
02-24-2026
02-19-2026
Dividend Yield
5.51%
N/A
EPS Growth
N/A
N/A
EPS
2.96
N/A
Revenue
$4,850,258,000.00
$469,820,000.00
Revenue This Year
N/A
$31.15
Revenue Next Year
N/A
$24.15
P/E Ratio
$31.89
N/A
Revenue Growth
9.04
30.38
52 Week Low
$79.83
$73.16
52 Week High
$129.32
$163.71

Technical Indicators

Market Signals
Indicator
CHRD
GKOS
Relative Strength Index (RSI) 49.38 58.14
Support Level $87.35 $109.07
Resistance Level $95.09 $115.00
Average True Range (ATR) 2.86 2.76
MACD -0.00 -0.95
Stochastic Oscillator 53.50 44.01

Price Performance

Historical Comparison
CHRD
GKOS

About CHRD Chord Energy Corporation

Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: